Moleculin Biotech CS (MBRX)

$2.06 0.00 (N/A)
Market Cap 4.20M
Revenue (ttm) 0.00
Net Income (ttm) -21.76M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 79,600
Avg Vol 179,010
Day's Range N/A - N/A
Shares Out 2.04M
Stochastic %K 50%
Beta 1.73
Analysts Strong Sell
Price Target $21.00

Company Profile

Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases. The company is also developing WP1066 portfolio, including WP1066, WP1193, and WP1220, which are immune/transcription modulators designed to...

Industry: Biotechnology
Sector: Healthcare
Phone: 713 300 5160
Address:
5300 Memorial Drive, Suite 950, Houston, United States
Brokechump
Brokechump Mar. 20 at 9:03 PM
$MBRX
0 · Reply
quito_yume
quito_yume Mar. 19 at 9:23 PM
$MBRX Remember back before the last 2 reverse splits when Wally said that investors were about to be rewarded! Bwaahahahahaaa!! It's only him that has been rewarded and with your money.
0 · Reply
DARKP00L
DARKP00L Mar. 19 at 12:53 PM
$MBRX 08:45 on Mar. 19 2026 Moleculin Biotech Confirms 45-Patient Interim Data Unblinding In Pivotal MIRACLE Trial On Track For Mid-2026 #tradeideas
0 · Reply
Stock_Catcher
Stock_Catcher Mar. 19 at 12:36 PM
$MBRX ​​MBRX Moleculin Reports Full Year 2025 Financial Results and Confirms Highly Anticipated 45-Patient Interim Data Unblinding in Pivotal MIRACLE Trial On Track for Mid-2026
0 · Reply
mokaz1
mokaz1 Mar. 18 at 4:24 PM
$MBRX
0 · Reply
mokaz1
mokaz1 Mar. 18 at 4:08 PM
$MBRX
0 · Reply
llchen1204
llchen1204 Mar. 17 at 3:52 PM
$MBRX
0 · Reply
IVALTE
IVALTE Mar. 17 at 3:06 PM
$MBRX vamos hijaputa no pares hasta $133
0 · Reply
Brokechump
Brokechump Mar. 16 at 8:18 PM
$MBRX like to see green!!
0 · Reply
johndoe40
johndoe40 Mar. 16 at 5:21 PM
$MBRX This tells you all you need to know about this group...
0 · Reply
Latest News on MBRX
Moleculin Reports Full Year 2025 Financial Results and Confirms Highly Anticipated 45-Patient Interim Data Unblinding in Pivotal MIRACLE Trial On Track for Mid-2026

Mar 19, 2026, 8:36 AM EDT - 2 days ago

Moleculin Reports Full Year 2025 Financial Results and Confirms Highly Anticipated 45-Patient Interim Data Unblinding in Pivotal MIRACLE Trial On Track for Mid-2026

Moleculin to Present at 38th Annual ROTH Conference

Mar 17, 2026, 9:05 AM EDT - 4 days ago

Moleculin to Present at 38th Annual ROTH Conference

Moleculin Releases Next CEO Corner Segment Highlighting MIRACLE Study

Mar 11, 2026, 9:00 AM EDT - 10 days ago

Moleculin Releases Next CEO Corner Segment Highlighting MIRACLE Study

Moleculin Announces Exercise of Warrants for $8.3 Million Gross Proceeds

Feb 19, 2026, 8:39 AM EST - 4 weeks ago

Moleculin Announces Exercise of Warrants for $8.3 Million Gross Proceeds

Moleculin MIRACLE Trial Delivers 40% Preliminary Blinded CRc Rate (n=30)

Feb 18, 2026, 8:20 AM EST - 4 weeks ago

Moleculin MIRACLE Trial Delivers 40% Preliminary Blinded CRc Rate (n=30)

Moleculin Announces Notice of Allowance for Japanese Patent Covering Annamycin

Feb 17, 2026, 8:35 AM EST - 4 weeks ago

Moleculin Announces Notice of Allowance for Japanese Patent Covering Annamycin

Moleculin Launches CEO Corner Platform to Share Strategic Insights

Feb 13, 2026, 8:32 AM EST - 5 weeks ago

Moleculin Launches CEO Corner Platform to Share Strategic Insights

Moleculin to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial

Feb 5, 2026, 9:15 AM EST - 6 weeks ago

Moleculin to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial

Moleculin Reports Independent Assessment Confirms No Cardiotoxicity of Annamycin in 90 Subjects

Jan 13, 2026, 8:55 AM EST - 2 months ago

Moleculin Reports Independent Assessment Confirms No Cardiotoxicity of Annamycin in 90 Subjects

Moleculin Accelerates Outlook Into 2026 With First Pivotal Trial Unblinding on Track, Global Trial Expansion, and Multiple Externally/IIT Funded Clinical Programs

Jan 12, 2026, 8:36 AM EST - 2 months ago

Moleculin Accelerates Outlook Into 2026 With First Pivotal Trial Unblinding on Track, Global Trial Expansion, and Multiple Externally/IIT Funded Clinical Programs

Moleculin Announces Positive Results from Phase 1 Clinical Trial Evaluating WP1066 for the Treatment of Pediatric Recurrent Malignant Brain Tumors

Dec 17, 2025, 8:31 AM EST - 3 months ago

Moleculin Announces Positive Results from Phase 1 Clinical Trial Evaluating WP1066 for the Treatment of Pediatric Recurrent Malignant Brain Tumors

Moleculin Announces Exercise of Warrants for $6.8 Million Gross Proceeds

Dec 10, 2025, 8:30 AM EST - 3 months ago

Moleculin Announces Exercise of Warrants for $6.8 Million Gross Proceeds

Moleculin Announces Completion of Treatment for the 45 Patients in Pivotal “MIRACLE” Phase 3 AML Trial on Pace for Q1 2026

Dec 9, 2025, 8:07 AM EST - 3 months ago

Moleculin Announces Completion of Treatment for the 45 Patients in Pivotal “MIRACLE” Phase 3 AML Trial on Pace for Q1 2026

Moleculin Announces New Annamycin Collaboration in Brain Tumors

Dec 8, 2025, 8:21 AM EST - 3 months ago

Moleculin Announces New Annamycin Collaboration in Brain Tumors

Moleculin to Participate in the Virtual Investor Closing Bell Series

Nov 26, 2025, 9:15 AM EST - 4 months ago

Moleculin to Participate in the Virtual Investor Closing Bell Series

Moleculin Announces Reverse Stock Split

Nov 26, 2025, 9:00 AM EST - 4 months ago

Moleculin Announces Reverse Stock Split

Moleculin Reports 60% of First 45 Subjects in Pivotal “MIRACLE” Phase 3 AML Trial Consented

Nov 13, 2025, 8:36 AM EST - 4 months ago

Moleculin Reports 60% of First 45 Subjects in Pivotal “MIRACLE” Phase 3 AML Trial Consented

Moleculin Announces Grant Funded Research Evaluating Annamycin for the Treatment of Pancreatic Cancer at UNC-Chapel Hill

Nov 12, 2025, 8:37 AM EST - 4 months ago

Moleculin Announces Grant Funded Research Evaluating Annamycin for the Treatment of Pancreatic Cancer at UNC-Chapel Hill

Moleculin to Highlight its Ongoing Phase 3 Acute Myeloid Leukemia “MIRACLE” Clinical Trial at the 14th Annual Acute Leukemia Meeting

Oct 30, 2025, 8:40 AM EDT - 5 months ago

Moleculin to Highlight its Ongoing Phase 3 Acute Myeloid Leukemia “MIRACLE” Clinical Trial at the 14th Annual Acute Leukemia Meeting

Moleculin Expands Global IP Portfolio with New Australian Patent for Annamycin

Oct 29, 2025, 8:35 AM EDT - 5 months ago

Moleculin Expands Global IP Portfolio with New Australian Patent for Annamycin

Moleculin Announces New Investigator-Initiated Study of Annamycin for Treating Pancreatic Cancer

Oct 23, 2025, 8:00 AM EDT - 5 months ago

Moleculin Announces New Investigator-Initiated Study of Annamycin for Treating Pancreatic Cancer

Moleculin Announces Notice of Allowance for Canadian Patent Covering Annamycin

Sep 25, 2025, 8:35 AM EDT - 6 months ago

Moleculin Announces Notice of Allowance for Canadian Patent Covering Annamycin

Moleculin Accelerates Recruitment in Phase 3 Acute Myeloid Leukemia “MIRACLE” Clinical Trial

Sep 9, 2025, 8:45 AM EDT - 6 months ago

Moleculin Accelerates Recruitment in Phase 3 Acute Myeloid Leukemia “MIRACLE” Clinical Trial

Moleculin Doses First EU Patient in Phase 3 Pivotal MIRACLE Trial for Treatment of Acute Myeloid Leukemia

Sep 8, 2025, 8:30 AM EDT - 6 months ago

Moleculin Doses First EU Patient in Phase 3 Pivotal MIRACLE Trial for Treatment of Acute Myeloid Leukemia

Moleculin Announces Exercise of Warrants for $6.0 Million Gross Proceeds

Aug 28, 2025, 8:30 AM EDT - 7 months ago

Moleculin Announces Exercise of Warrants for $6.0 Million Gross Proceeds

Moleculin Issues New Positive AML Overall Survival Data:

Aug 27, 2025, 8:45 AM EDT - 7 months ago

Moleculin Issues New Positive AML Overall Survival Data:

Moleculin to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

Aug 14, 2025, 9:15 AM EDT - 7 months ago

Moleculin to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

Moleculin Reports Second Quarter 2025 Financial Results and Highlights

Aug 13, 2025, 8:05 AM EDT - 7 months ago

Moleculin Reports Second Quarter 2025 Financial Results and Highlights

Moleculin Biotech, Inc. Unveils Promising Preclinical Data of Annamycin in Liver Cancer Treatment

Aug 6, 2025, 8:40 AM EDT - 8 months ago

Moleculin Biotech, Inc. Unveils Promising Preclinical Data of Annamycin in Liver Cancer Treatment

Moleculin Receives Notice of Intent to Grant New European Patent for Annamycin

Jul 30, 2025, 8:35 AM EDT - 8 months ago

Moleculin Receives Notice of Intent to Grant New European Patent for Annamycin

Moleculin Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference

Jul 22, 2025, 8:45 AM EDT - 8 months ago

Moleculin Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference

Moleculin Engages Industry Veteran Adriano Treve to Explore Accelerated Strategic Partnerships

Jul 17, 2025, 8:25 AM EDT - 8 months ago

Moleculin Engages Industry Veteran Adriano Treve to Explore Accelerated Strategic Partnerships

Moleculin Expands Phase 3 MIRACLE Clinical Trial into the Country of Georgia, Enrollment Update and Future Plans

Jul 9, 2025, 8:35 AM EDT - 9 months ago

Moleculin Expands Phase 3 MIRACLE Clinical Trial into the Country of Georgia, Enrollment Update and Future Plans

Moleculin Announces $5.9 Million Public Offering

Jun 20, 2025, 9:20 AM EDT - 9 months ago

Moleculin Announces $5.9 Million Public Offering

Moleculin Participates in Virtual Investor “What This Means” Segment

Jun 18, 2025, 7:45 AM EDT - 9 months ago

Moleculin Participates in Virtual Investor “What This Means” Segment

Moleculin Receives Positive FDA Feedback on Pediatric Study Plan for Annamycin in Children with R/R AML

Jun 18, 2025, 7:30 AM EDT - 9 months ago

Moleculin Receives Positive FDA Feedback on Pediatric Study Plan for Annamycin in Children with R/R AML

Moleculin Releases On-Demand KOL Webcast to Discuss Data from its Phase 1B/2 Study of Annamycin for the Treatment of Soft Tissue Sarcoma (STS) Lung Metastases (MB-107)

Jun 5, 2025, 8:00 AM EDT - 10 months ago

Moleculin Releases On-Demand KOL Webcast to Discuss Data from its Phase 1B/2 Study of Annamycin for the Treatment of Soft Tissue Sarcoma (STS) Lung Metastases (MB-107)

Moleculin Reports Positive Topline Efficacy Results from U.S. Phase 1B/2 Clinical Trial Evaluating Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases (MB-107)

Jun 4, 2025, 8:45 AM EDT - 10 months ago

Moleculin Reports Positive Topline Efficacy Results from U.S. Phase 1B/2 Clinical Trial Evaluating Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases (MB-107)

Moleculin Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 14, 2025, 7:30 AM EDT - 11 months ago

Moleculin Reports First Quarter 2025 Financial Results and Provides Corporate Update

Moleculin Receives European Medicines Agency Approval to Expand Phase 3 MIRACLE Clinical Trial

May 12, 2025, 8:40 AM EDT - 11 months ago

Moleculin Receives European Medicines Agency Approval to Expand Phase 3 MIRACLE Clinical Trial

Moleculin to Report First Quarter 2025 Financial Results on May 13, 2025 and Host Conference Call and Webcast

May 7, 2025, 9:00 AM EDT - 11 months ago

Moleculin to Report First Quarter 2025 Financial Results on May 13, 2025 and Host Conference Call and Webcast

Moleculin Announces World Health Organization Approval of “naxtarubicin” as International Non-Proprietary Name for Annamycin

May 6, 2025, 9:00 AM EDT - 11 months ago

Moleculin Announces World Health Organization Approval of “naxtarubicin” as International Non-Proprietary Name for Annamycin

Moleculin Bolsters Annamycin Intellectual Property Portfolio with Granting of Two New U.S. Patents

May 5, 2025, 8:45 AM EDT - 11 months ago

Moleculin Bolsters Annamycin Intellectual Property Portfolio with Granting of Two New U.S. Patents

Moleculin Announces New Pre-Clinical Data for Annamycin Demonstrating Market Expansion Potential Including Treatment for Pancreatic Cancer

Apr 29, 2025, 8:35 AM EDT - 11 months ago

Moleculin Announces New Pre-Clinical Data for Annamycin Demonstrating Market Expansion Potential Including Treatment for Pancreatic Cancer

Moleculin Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025

Apr 17, 2025, 8:30 AM EDT - 1 year ago

Moleculin Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025

Moleculin Doses First Patient in Pivotal, Adaptive Phase 3 MIRACLE Trial

Apr 1, 2025, 8:30 AM EDT - 1 year ago

Moleculin Doses First Patient in Pivotal, Adaptive Phase 3 MIRACLE Trial

Moleculin Reports Full Year 2024 Financial Results and Provides Corporate Update

Mar 24, 2025, 7:05 AM EDT - 1 year ago

Moleculin Reports Full Year 2024 Financial Results and Provides Corporate Update

Moleculin to Report Full Year 2024 Financial Results on March 21, 2025 and Host Conference Call and Webcast

Mar 19, 2025, 8:05 AM EDT - 1 year ago

Moleculin to Report Full Year 2024 Financial Results on March 21, 2025 and Host Conference Call and Webcast

Moleculin Biotech, Inc. Participates in the Virtual Investor "Top 5 for '25" On-Demand Conference

Mar 11, 2025, 8:45 AM EDT - 1 year ago

Moleculin Biotech, Inc. Participates in the Virtual Investor "Top 5 for '25" On-Demand Conference

Moleculin to Present at the 37th Annual ROTH Conference

Mar 10, 2025, 8:45 AM EDT - 1 year ago

Moleculin to Present at the 37th Annual ROTH Conference

Brokechump
Brokechump Mar. 20 at 9:03 PM
$MBRX
0 · Reply
quito_yume
quito_yume Mar. 19 at 9:23 PM
$MBRX Remember back before the last 2 reverse splits when Wally said that investors were about to be rewarded! Bwaahahahahaaa!! It's only him that has been rewarded and with your money.
0 · Reply
DARKP00L
DARKP00L Mar. 19 at 12:53 PM
$MBRX 08:45 on Mar. 19 2026 Moleculin Biotech Confirms 45-Patient Interim Data Unblinding In Pivotal MIRACLE Trial On Track For Mid-2026 #tradeideas
0 · Reply
Stock_Catcher
Stock_Catcher Mar. 19 at 12:36 PM
$MBRX ​​MBRX Moleculin Reports Full Year 2025 Financial Results and Confirms Highly Anticipated 45-Patient Interim Data Unblinding in Pivotal MIRACLE Trial On Track for Mid-2026
0 · Reply
mokaz1
mokaz1 Mar. 18 at 4:24 PM
$MBRX
0 · Reply
mokaz1
mokaz1 Mar. 18 at 4:08 PM
$MBRX
0 · Reply
llchen1204
llchen1204 Mar. 17 at 3:52 PM
$MBRX
0 · Reply
IVALTE
IVALTE Mar. 17 at 3:06 PM
$MBRX vamos hijaputa no pares hasta $133
0 · Reply
Brokechump
Brokechump Mar. 16 at 8:18 PM
$MBRX like to see green!!
0 · Reply
johndoe40
johndoe40 Mar. 16 at 5:21 PM
$MBRX This tells you all you need to know about this group...
0 · Reply
johndoe40
johndoe40 Mar. 16 at 5:13 PM
$MBRX
0 · Reply
Brokechump
Brokechump Mar. 15 at 10:28 PM
$MBRX I bet we go up or down, maybe sideways this week. Not financial advice. Just shook my magic 8 ball. Is what it is.
0 · Reply
kyly2
kyly2 Mar. 12 at 5:53 PM
$MBRX 💪
0 · Reply
johndoe40
johndoe40 Mar. 11 at 8:49 PM
$MBRX
0 · Reply
AZOZ
AZOZ Mar. 11 at 7:34 PM
$MBRX Double bottom keep it under the radar guys 📡
0 · Reply
Brokechump
Brokechump Mar. 11 at 7:09 PM
$MBRX whoever is buying thank you. Thought my phome froze for a sec.
0 · Reply
Brokechump
Brokechump Mar. 11 at 6:21 PM
$MBRX Like watching paint dry
0 · Reply
Brokechump
Brokechump Mar. 11 at 1:16 PM
$MBRX
0 · Reply
Brokechump
Brokechump Mar. 11 at 1:15 PM
$MBRX News a plus.
0 · Reply
mokaz1
mokaz1 Mar. 10 at 7:11 PM
$MBRX If you value your money, stay the hell away from MBRX.
1 · Reply
Kinderla
Kinderla Mar. 10 at 3:47 PM
$MBRX This stock looks like a good setup to me. Trading near an all time low, data expected to be released soon and preliminary info on it is optimistic. Also, they recently completed some financing with warrants at $3.60 so that could act as a magnet. Thoughts?
2 · Reply
Kinderla
Kinderla Mar. 10 at 2:49 PM
$MBRX $MBRX If you are not familiar with Alex and http://BioStockInfo.com, you should be. He puts out a lot of great information for free and he isn’t trying to sell you anything. He will also actually respond to your questions. He has $MBRX as the top stock in his weekly scanner two weeks in a row. You can check it out here: https://www.biostockinfo.com/biotech-catalyst-ai-scanner-march-wk122026/
0 · Reply